David R. Matthews, MA, DPhil, BM, BCh, FRCP


September 30, 2013

This feature requires the newest version of Flash. You can download it here.
In This Article

Remembering the Impact of UKPDS

Hi. I am David Matthews, Professor of Diabetes Medicine at the University of Oxford in the United Kingdom. We are here in Barcelona at the European Association for the Study of Diabetes (EASD) meeting. Of interest, it was in Barcelona 15 years ago that the first results of the UK Prospective Diabetes Study (UKPDS)[1] were disclosed. That was a big meeting. UKPDS was an important landmark study in the UK. It was coordinated by principal investigator Robert Turner who, unfortunately, died a year or so later, and by Professor Rory Holman, who has continued to be the principal investigator of the UKPDS and has done a huge amount of work over the years.

The amount of work that has been done can be measured by the fact that there are now 82 papers from the UKPDS,[2] and citations of the papers number more than 37,000 altogether. So it has had a huge impact, and this year we are again celebrating by having a retrospective and saying, "What is the impact, what is the overview of the UKPDS, and how has it changed the way that we think?"

It has changed the way we think in a remarkable number of ways. It was the first big study of early-onset diabetes. In other words, we took people who were diagnosed and randomly assigned them at that point. Many other trials later on were taking people who had been, say, 10 years into diabetes. But this was the first big trial to take newly diagnosed patients with type 2 diabetes and randomly assign them either to an intensive treatment arm or to a conventional treatment arm.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.